Patents by Inventor Jay Hooper

Jay Hooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Systems and Methods for the Production of Human Polyclonal Antibodies
    Publication number: 20220153817
    Abstract: Disclosed herein is a method for producing human antibodies against a pathogen comprising injecting a non-human animal with a pathogen-derived DNA vaccine in at least two locations of the animal; injecting the animal with an adjuvant in a location of the animal different from the location of the DNA vaccine location; collecting plasma from the animal after the injections; and purifying polyclonal antibody from the plasma.
    Type: Application
    Filed: June 30, 2021
    Publication date: May 19, 2022
    Inventors: Jay HOOPER, Eddie SULLIVAN, Hua WU
  • SIN NOMBRE VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES
    Publication number: 20220090136
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 24, 2022
    Inventor: Jay HOOPER
  • Sin Nombre virus full-length M segment-based DNA vaccines
    Patent number: 11155834
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: October 26, 2021
    Inventor: Jay Hooper
  • Systems and methods for the production of human polyclonal antibodies
    Patent number: 11072649
    Abstract: Disclosed herein is a method for producing human antibodies against a pathogen comprising injecting a non-human animal with a pathogen-derived DNA vaccine in at least two locations of the animal; injecting the animal with an adjuvant in a location of the animal different from the location of the DNA vaccine location; collecting plasma from the animal after the injections; and purifying polyclonal antibody from the plasma.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: July 27, 2021
    Assignee: SAB, LLC
    Inventors: Jay Hooper, Eddie Sullivan, Hua Wu
  • SIN NOMBRE VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES
    Publication number: 20200102576
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Application
    Filed: August 28, 2019
    Publication date: April 2, 2020
    Applicant: The Government of the United States, as represented by the Secretary of the Army
    Inventor: Jay Hooper
  • Therapeutic compositions for neutralizing type I interferons, and methods of use
    Patent number: 10548946
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: February 4, 2020
    Assignee: The government of the United States, as represented by the Secretary of the Army
    Inventors: Joseph Golden, Jay Hooper
  • Sin Nombre virus full-length M segment-based DNA vaccines
    Patent number: 10443073
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 15, 2019
    Assignee: The Government of the United States, as represented by the Secretary of the Army
    Inventor: Jay Hooper
  • THERAPEUTIC COMPOSITIONS FOR NEUTRALIZING TYPE I INTERFERONS, AND METHODS OF USE
    Publication number: 20180110826
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Application
    Filed: December 1, 2017
    Publication date: April 26, 2018
    Applicant: The United States of America, as represented by the Secretary of the Army, on behalf of the United
    Inventors: JOSEPH GOLDEN, JAY HOOPER
  • Therapeutic compositions for neutralizing type I interferons, and methods of use
    Patent number: 9861681
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: January 9, 2018
    Assignee: The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases
    Inventors: Joseph Golden, Jay Hooper
  • Systems and Methods for the Production of Human Polyclonal Antibodies
    Publication number: 20170233459
    Abstract: Disclosed herein is a method for producing human antibodies against a pathogen comprising injecting a non-human animal with a pathogen-derived DNA vaccine in at least two locations of the animal; injecting the animal with an adjuvant in a location of the animal different from the location of the DNA vaccine location; collecting plasma from the animal after the injections; and purifying polyclonal antibody from the plasma.
    Type: Application
    Filed: November 25, 2016
    Publication date: August 17, 2017
    Inventors: Jay Hooper, W, Eddie Sullivan, Hua Wu
  • SIN NOMBRE VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES
    Publication number: 20160346376
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Application
    Filed: March 25, 2016
    Publication date: December 1, 2016
    Applicant: The United States of America, as rep. by the Sec'y of the Army, for U.S. Army Medical Research Insti
    Inventor: JAY HOOPER
  • Nucleic acids containing a synthetic codon-optimized Sin Nombre virus full-length M gene
    Patent number: 9315826
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 19, 2016
    Assignee: The United States of America as rep. by the Sec'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases
    Inventor: Jay Hooper
  • THERAPEUTIC COMPOSITIONS FOR NEUTRALIZING TYPE I INTERFERONS, AND METHODS OF USE
    Publication number: 20160089418
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Application
    Filed: April 15, 2014
    Publication date: March 31, 2016
    Inventors: JOSEPH GOLDEN, JAY HOOPER
  • Puumala virus full-length M segment-based DNA vaccines
    Patent number: 8852598
    Abstract: The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: October 7, 2014
    Inventor: Jay Hooper
  • Sin Nombre Virus Full-Length M Segment-Based DNA Vaccines
    Publication number: 20140079731
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Application
    Filed: January 31, 2011
    Publication date: March 20, 2014
    Applicant: The United States of America as rep. by the Sec'y the army for U.S. Army Medical Research Institute
    Inventor: Jay Hooper
  • PUUMALA VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES
    Publication number: 20130273170
    Abstract: The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus.
    Type: Application
    Filed: April 11, 2012
    Publication date: October 17, 2013
    Inventor: Jay Hooper
  • Puumala virus full-length M segment-based DNA vaccines
    Patent number: 8183358
    Abstract: The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: May 22, 2012
    Assignee: The United States of America, as represented by the Secretary of the Army
    Inventor: Jay Hooper
  • PUUMALA VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES
    Publication number: 20100323024
    Abstract: The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus.
    Type: Application
    Filed: February 12, 2008
    Publication date: December 23, 2010
    Inventor: Jay Hooper